Arjun Agarwal Buys Shares of Oruka Therapeutics
Arjun Agarwal, SVP of Finance at Oruka Therapeutics, purchased 9,459 shares.
Key Points
- Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, bought 9,459 shares on June 12, 2026, at an average price of $15.88 each.
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) has a market cap of $4.22 billion and traded at $69.89 recently, with a 52-week high of $91.00.
- Analysts maintain a strong buy consensus on Oruka Therapeutics, with a mean price target of $142.17 and recent targets ranging from $70 to $200.
Arjun Agarwal, the Senior Vice President of Finance at Oruka Therapeutics, Inc. (NASDAQ: ORKA), made a significant move on June 12, 2026, by purchasing 9,459 shares of the company. This transaction, valued at approximately $150,175, was executed at an average price of $15.88 per share.
Insider Buying and Selling at Oruka Therapeutics, Inc.
Arjun Agarwal's recent purchase highlights insider activity at Oruka Therapeutics. On June 15, 2026, Joana Goncalves, Chief Medical Officer, bought 7,000 shares at $7.32 each, while also selling 3,500 shares. Additionally, Laura Lee Sandler, the Chief Operating Officer, sold 600 shares at $69.69. Agarwal sold 395 shares on June 15 under a planned transaction.
Other Institutional Activity in Oruka Therapeutics
Institutional investors have also been active in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, bringing its total to 7,431,403 shares valued at approximately $364.51 million. Meanwhile, Paradigm Biocapital Advisors LP significantly boosted its position by 610,000 shares, ending with 2,320,316 shares worth about $113.81 million. BlackRock, Inc. slightly reduced its stake by 12,328 shares, holding 3,527,087 shares valued at $173.00 million.
Oruka Therapeutics Stock Snapshot
Shares of Oruka Therapeutics are trading near $69.89. The company boasts a market cap of $4.22 billion. Although the forward P/E ratio is not meaningful due to negative earnings, the stock has shown a 52-week range between $10.77 and $91.00. It has a 50-day moving average of $63.70 and a 200-day moving average of $37.60. Oruka's financial health is strong with a current ratio of 23.76 and a quick ratio of 23.38.
Analysts Set New Price Targets
Analysts are optimistic about Oruka Therapeutics, with several firms maintaining a 'buy' rating. On May 14, 2026, BTIG reiterated its 'buy' rating with a target price of $151. HC Wainwright & Co. and UBS also maintained their 'buy' ratings with target prices of $120 and $100, respectively. The consensus among analysts is a 'strong buy', with a mean price target of $142.17.
About Oruka Therapeutics
Oruka Therapeutics, Inc., headquartered in Menlo Park, California, is a clinical-stage biopharmaceutical company in the healthcare sector. It focuses on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory diseases. The company's leading products, ORKA-001 and ORKA-002, are in phase 2 trials targeting interleukin pathways. Dr. Lawrence Otto Klein serves as the CEO, guiding a team of 68 employees.
Bottom Line
Arjun Agarwal's recent purchase of Oruka Therapeutics shares reflects a notable insider confidence in the company's future. Investors often monitor such transactions for insights into company prospects. While insider buying can be a positive signal, it's important to remember that these transactions are not recommendations. The information is based on filings and may not represent current holdings.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.